Today: 16 May 2026
Browse Category

Earnings Reports 4 January 2026 - 5 January 2026

MercadoLibre stock slides into 2026 as MELI investors eye Feb. 24 earnings and a big U.S. data week

MercadoLibre stock slides into 2026 as MELI investors eye Feb. 24 earnings and a big U.S. data week

MercadoLibre Inc shares fell 2.0% to $1,973.70 on Friday, closing about $110 below their 50-day moving average and $294 under the 200-day. The drop outpaced U.S. benchmarks as the company heads into its first full trading week under new CEO Ariel Szarfsztejn. Investors await Monday’s ISM data and the December jobs report later in the week. Fourth-quarter results are scheduled for Feb. 24.
5 January 2026
··
Applied Digital stock (APLD) jumps 15% into earnings week as ChronoScale spin-out plan sharpens focus

Applied Digital stock (APLD) jumps 15% into earnings week as ChronoScale spin-out plan sharpens focus

Applied Digital shares surged 14.6% to close at $28.11 Friday on heavy volume. The company will report fiscal Q2 results after markets close Jan. 7 and hold a conference call at 5 p.m. ET. Investors await updates on a proposed cloud business spin-out with Ekso Bionics and new financing for AI-focused data centers. A subsidiary secured up to $100 million in credit from Macquarie Equipment Capital at 8% interest.
5 January 2026
···
Workday (WDAY) stock hugs 52-week low after Friday slide as focus shifts to jobs data, next earnings

Workday (WDAY) stock hugs 52-week low after Friday slide as focus shifts to jobs data, next earnings

Workday shares dropped 4.2% to $205.79 on Friday, hitting a 52-week low of $202.22. The decline came as the S&P 500 rose 0.19% and investors watched interest-rate moves. Workday’s fiscal fourth-quarter results are due in late February, with subscription growth and guidance in focus. The company’s planned acquisition of Pipedream is expected to close this quarter.
5 January 2026
··
IBM stock slips below $300 as Wall Street braces for jobs data and Big Blue earnings

IBM stock slips below $300 as Wall Street braces for jobs data and Big Blue earnings

IBM shares closed down 1.6% at $291.50 Friday, falling below $300 after touching $289.00 intraday. The move comes ahead of key U.S. jobs and inflation data next week and IBM’s preliminary fourth-quarter earnings set for Jan. 28. Directors Michael Miebach and Peter R. Voser deferred fees into stock units, according to SEC filings. IBM sits about 10% below its 52-week high of $324.90.
5 January 2026
··
Costco stock drifts near 52-week low ahead of December sales report — here’s what matters next

Costco stock drifts near 52-week low ahead of December sales report — here’s what matters next

Costco shares closed Friday down 0.9% at $854.50, near a 52-week low ahead of December sales results due Jan. 7. Analyst Joseph Feldman expects December comparable sales growth to slow to 2.2% from 7.4% last year. The stock remains below key technical levels and lags the broader market. Gasoline prices and currency shifts are expected to impact reported figures.
5 January 2026
··
Mastercard stock slides into 2026 after four-day skid; jobs report and earnings date loom

Mastercard stock slides into 2026 after four-day skid; jobs report and earnings date loom

Mastercard shares fell 1.36% to $563.13 on Friday, marking a fourth consecutive decline and closing about 6% below their 52-week high. Trading volume was above average as investors await the U.S. jobs report on Jan. 9 and Mastercard’s expected earnings on Jan. 29. Visa also slipped, while major banks gained. Mastercard’s board declared a quarterly dividend and approved a $14 billion buyback.
5 January 2026
··
UnitedHealth stock rises into the weekend — what UNH investors watch before Jan. 27 results

UnitedHealth stock rises into the weekend — what UNH investors watch before Jan. 27 results

UnitedHealth Group shares rose 1.9% to $336.40 Friday, trading 6.9 million shares and closing above key moving averages. The company will report full-year results and its 2026 outlook before the market opens Jan. 27. UnitedHealth remains under Justice Department investigation over billing practices. The stock is well below its 52-week high of $606.36.
5 January 2026
····
JPMorgan stock holds near record highs as Wall Street braces for Jan. 13 earnings and key U.S. data

JPMorgan stock holds near record highs as Wall Street braces for Jan. 13 earnings and key U.S. data

JPMorgan Chase shares rose $3.26 to $325.48 Friday, closing above key moving averages as investors await its Jan. 13 earnings. The 10-year Treasury yield climbed to 4.191%, while peers Wells Fargo and Bank of America outperformed JPM on the day. A director deferred compensation into 174.57 shares at $322.22 each, according to an SEC filing. Jobs data and inflation reports next week may drive volatility in bank stocks.
4 January 2026
··
Robinhood stock sets Feb. 10 earnings date — here’s what HOOD traders watch next

Robinhood stock sets Feb. 10 earnings date — here’s what HOOD traders watch next

Robinhood will report fourth-quarter and full-year 2025 results on Feb. 10 after the bell, with a webcast at 5 p.m. ET. Shares closed Friday at $115.21, up 1.9% but about 25% below the 52-week high. U.S. payrolls data is due Jan. 9 and CPI on Jan. 13, both seen as key for rate expectations and trading activity. Investors will watch for updates on options, crypto, and new “event contracts.”
4 January 2026
··
1 … 160 161 162 163 164 … 248

Stock Market Today

  • W. R. Berkley (WRB) Shows 45.9% Undervaluation Despite Recent Price Stability
    May 15, 2026, 7:55 PM EDT. W. R. Berkley (WRB) stock has shown limited movement recently with a 1.2% gain over 7 days and a 4.2% decline year-to-date. Analysts use valuation methods like Excess Returns, which estimates intrinsic value by calculating profits above shareholder required returns. With an intrinsic value estimate of $122.79 against a current price near $66.45, the stock appears 45.9% undervalued. The insurer's steady underwriting profile and capital discipline contrast with sector concerns on insurance pricing and interest rate sensitivity. WRB currently scores 2 out of 6 on valuation metrics, highlighting potential but raising caution.

Latest articles

Accuray inks 10-year cancer tech agreement, shares in focus

Accuray inks 10-year cancer tech agreement, shares in focus

16 May 2026
Accuray and the University of Wisconsin School of Medicine and Public Health signed a 10-year research agreement focused on Accuray’s Stellar adaptive radiotherapy platform. The announcement came after market close, with Accuray shares ending down 5.2% at $0.27. The deal follows Accuray’s recent withdrawal of fiscal 2026 guidance and ongoing financial pressures.
Origin Materials Gains as Filing Signals $3.54 Liquidation Payout Possible

Origin Materials Gains as Filing Signals $3.54 Liquidation Payout Possible

16 May 2026
Origin Materials asked shareholders to approve a plan to liquidate and dissolve the company, estimating an initial payout of $0.61 to $3.54 per share depending on asset sales and claims. Shares rose 15% to $1.43 after the filing. The company reported a 91% drop in first-quarter revenue and warned it may not survive without the wind-down. Origin cut 59% of its workforce and CEO John Bissell stepped down May 1.
NextNRG Q1 Revenue Gains, but Company Holds Cash Warning

NextNRG Q1 Revenue Gains, but Company Holds Cash Warning

16 May 2026
NextNRG reported first-quarter revenue of $21.1 million, up 29% from a year earlier, but its net loss widened to $10.8 million. Cash fell to $208,048 at quarter-end, and management warned it needs immediate capital to continue operations. Shares closed at $0.2804 on Nasdaq, down nearly 6%. Total liabilities reached $34.3 million, with a stockholders’ deficit of $22 million.
HCW Biologics jumps 262% after Trimmune deal, Q1 profit, Nasdaq risk update

HCW Biologics jumps 262% after Trimmune deal, Q1 profit, Nasdaq risk update

16 May 2026
HCW Biologics shares jumped 262% to $1.22 Friday after the company posted a $3.47 million first-quarter profit, driven by a $6.5 million licensing deal with Beijing Trimmune Biotech. The company faces a possible Nasdaq delisting and will ask shareholders to approve a reverse stock split on June 15. HCW plans to report early Phase 1 data for its alopecia drug in the first half of 2026.
Go toTop